AB Science halts three non-priority masitinib clinical trials to focus on AML, ALS programs

• AB Science halted three non-priority masitinib trials to concentrate resources on AB8939 in acute myeloid leukemia and masitinib in ALS.
• The discontinued studies covered mast cell activation syndrome, mastocytosis, and progressive multiple sclerosis; the decision was not driven by masitinib safety.
• AB8939 program completed step 3 of its phase 1 combo study with venetoclax; the next step seeks clearance to start triple therapy with azacitidine.
• The phase 3 masitinib trial in ALS, authorized in 2025 but not started, will be revised before a restart request is filed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB Science SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607101149OMX_____CNEWS_FR_GNW1001212263_fr) on July 10, 2026, and is solely responsible for the information contained therein.